Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
出版年份 2018 全文链接
标题
Durable regression of Medulloblastoma after regional and intravenous delivery of anti-HER2 chimeric antigen receptor T cells
作者
关键词
Medulloblastoma, Chimeric antigen receptor T cell, HER2, Nonhuman primate
出版物
Journal for ImmunoTherapy of Cancer
Volume 6, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-04-30
DOI
10.1186/s40425-018-0340-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma
- (2017) Nabil Ahmed et al. JAMA Oncology
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma
- (2016) Giedre Krenciute et al. MOLECULAR THERAPY
- Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy
- (2016) Christine E. Brown et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
- (2016) Gregory L. Beatty et al. PHARMACOLOGY & THERAPEUTICS
- The Evolution of T-cell Therapies for Solid Malignancies
- (2015) K. Fousek et al. CLINICAL CANCER RESEARCH
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- Structural and functional features of central nervous system lymphatic vessels
- (2015) Antoine Louveau et al. NATURE
- 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
- (2015) Adrienne H Long et al. NATURE MEDICINE
- Rational development and characterization of humanized anti–EGFR variant III chimeric antigen receptor T cells for glioblastoma
- (2015) Laura A. Johnson et al. Science Translational Medicine
- Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes
- (2015) Lisa Liang et al. Oncotarget
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- 4-1BB Chimeric Antigen Receptors
- (2014) Dario Campana et al. CANCER JOURNAL
- Management of Pediatric and Adult Patients with Medulloblastoma
- (2014) Allison M. Martin et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- EGFRvIII mCAR-Modified T-Cell Therapy Cures Mice with Established Intracerebral Glioma and Generates Host Immunity against Tumor-Antigen Loss
- (2013) J. H. Sampson et al. CLINICAL CANCER RESEARCH
- Medulloblastoma expresses CD1d and can be targeted for immunotherapy with NKT cells
- (2013) Daofeng Liu et al. CLINICAL IMMUNOLOGY
- Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
- (2013) Michael C. Jensen et al. IMMUNOLOGICAL REVIEWS
- A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study
- (2013) Maryam Fouladi et al. JOURNAL OF NEURO-ONCOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The Future Is Now: Chimeric Antigen Receptors as New Targeted Therapies for Childhood Cancer
- (2012) D. W. Lee et al. CLINICAL CANCER RESEARCH
- T Cells Redirected to EphA2 for the Immunotherapy of Glioblastoma
- (2012) Kevin KH Chow et al. MOLECULAR THERAPY
- Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961
- (2012) Roger J. Packer et al. NEURO-ONCOLOGY
- Xenogeneic Graft-versus-Host-Disease in NOD-scid IL-2Rγnull Mice Display a T-Effector Memory Phenotype
- (2012) Niwa Ali et al. PLoS One
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- HER2-Specific T Cells Target Primary Glioblastoma Stem Cells and Induce Regression of Autologous Experimental Tumors
- (2010) N. Ahmed et al. CLINICAL CANCER RESEARCH
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
- (2010) Richard A Morgan et al. MOLECULAR THERAPY
- Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression
- (2009) Nabil Ahmed et al. MOLECULAR THERAPY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started